Bright Minds Biosciences files November update

Bright Minds Biosciences Inc. filed a Form 6-K as a foreign private issuer for November 2025.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Bright Minds Biosciences Inc. filed a Form 6-K as a foreign private issuer for November 2025. The filing furnishes a news release dated November 17, 2025 as Exhibit 99.1. That news release is incorporated by reference into the company’s two existing Form F-3 shelf registration statements.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bright Minds Biosciences (DRUG) file in November 2025?

Bright Minds Biosciences filed a Form 6-K as a foreign private issuer for November 2025. The report primarily furnishes a news release dated November 17, 2025 and ties it into existing registration statements.

What is included as Exhibit 99.1 in Bright Minds Biosciences’ November 2025 filing?

Exhibit 99.1 is a news release dated November 17, 2025 from Bright Minds Biosciences. This news release is formally submitted with the Form 6-K and becomes part of the company’s U.S. disclosure record.

How does the November 2025 Bright Minds (DRUG) 6-K affect its Form F-3 shelves?

The November 2025 6-K incorporates its Exhibit 99.1 news release into two Form F-3 registration statements. These are File No. 333-284694 and File No. 333-289851, effectively adding that disclosure to the shelf documents.

Which registration statements are referenced in Bright Minds Biosciences’ November 2025 report?

The report incorporates Exhibit 99.1 into two Form F-3 registration statements. One was originally filed on February 5, 2025, and the other was originally filed on August 25, 2025, each with its own file number.

Who signed Bright Minds Biosciences’ November 2025 Form 6-K?

The Form 6-K was signed on behalf of Bright Minds Biosciences Inc. by Ryan Cheung. He is identified in the document as the company’s Chief Financial Officer and executed the filing dated November 17, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 11/17/2025 - 05:11 PM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File No. 001-40997

BRIGHT MINDS BIOSCIENCES INC.
(Translation of registrant's name into English)

19 Vestry Street,
New York, NY 10013
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [ X ] Form 40-F [ ]

INCORPORATION BY REFERENCE

Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K is incorporated by reference into our (a) registration statement on Form F-3 (File No. 333-284694), originally filed on February 5, 2025, and the prospectus thereto filed on February 14, 2025, and (b) registration statement on Form F-3 (File No. 333-289851), originally filed on August 25, 2025.

SUBMITTED HEREWITH

Exhibits

99.1	News Release dated November 17, 2025

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BRIGHT MINDS BIOSCIENCES INC.

	(signed) "Ryan Cheung"
	Ryan Cheung
	Chief Financial Officer

Date: November 17, 2025

Source: View Original Filing on SEC EDGAR

Keep reading